ArticleAntibody therapeutics2026
Integrating fab phage and yeast display through seamless transfer of paired heavy- and light-chain libraries for efficient antibody discovery.
Article in Antibody therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Here, we developed an integrated phage-yeast display platform for efficient Fab antibody discovery. We transferred paired Fab libraries from phage output into yeast display vectors while preserving VH-VL pairings with the engineered compatible Fab display vectors that we developed for both phage and yeast. Specifically, we identified restriction enzyme sites that are rare in antibody variable regions and designed novel signal peptides compatible with these sites for Fab display. These signal peptides performed at least as well as commonly used benchmarks (such as PelB or StII for phage display, and AGA2 or MFAL1 for yeast display) in bio-panning experiments. Our modular vector architecture supports straightforward library shuttling across mouse-derived, fully human, and naïve Fab libraries. Results: Using a mouse immune Fab library, we applied our integrated platform to isolate antibodies against a soluble protein. Following two rounds of liquid-phase phage display and four rounds of fluorescence-activated cell sorting combined with a yeast-based receptor-blocking screening method developed herein, we successfully isolated antigen-specific Fabs with sub-nanomolar affinities and potent receptor-blocking activity. Conclusions: Our integrated approach leverages the capacity of phage display to screen large Fab libraries while harnessing the strength of yeast display for functional screening, exemplified here by the successful identification of receptor-blocking antibodies, thereby streamlining the discovery of high-quality Fab candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.